Microbiome And Microbiome Derived Metabolic Products As Modifiers Of Appetite And Treatments For Obesity And Metabolic Diseases Alone Or In Combination With Existing Weight Loss Interventions

Tech ID: 29505 / UC Case 2017-531-0


UCLA researchers in the Department of Medicine at the David Geffen School of Medicine have developed a novel treatment strategy for obesity and metabolic syndromes to improve outcomes of weight loss interventions, especially sleeve gastrectomy and gastric bypass.


Obesity, defined as a body mass index ≥ 30 kg/m2, is a chronic illness identified in children, adolescents, and adults. In the United States, 35% of adults and 17% of children are obese. Examples of well-established health hazards associated with obesity include type II diabetes, hypertension, cardiovascular disease, liver disease, and osteoarthritis. Medical and behavioral approaches to weight loss can reduce the risk of developing these complications or improve medical conditions, and bariatric surgical procedures are becoming increasingly common because of their efficacy in weight reduction and improved management of diabetes and hypertension. Both gastric bypass and sleeve gastrectomy are associated with reduced hunger scores and changes in food preferences, including a marked reduction in the preference for high-calorie foods. Interestingly, bariatric surgery induces changes in the gastrointestinal tract anatomy, physiology and luminal environment, which in turn significantly affect the gut microbiome.


Based on assessment of gut microbiota in obese subjects, researchers at UCLA have found several bacteria that are associated with better outcomes of weight loss at 6 months after bariatric surgery. They also found that gut microbiome-derived metabolites, including those derived from fermentation of amino acids, could be used to modify appetite. Thus, a probiotic/symbiotic product containing these bacteria or gut microbiome-derived metabolites can be administered prior to bariatric surgery or soon after surgery to enrich gut microbiota for improved weight loss outcome. Alternatively, the same strategy can be used to improve weight loss after other interventions for obesity and metabolic syndrome.


  • Improve weight loss outcomes with bariatric surgery or other interventions for obesity and metabolic syndrome


  • Potentially replace weight loss surgery or decrease the number of failed bariatric surgeries

State Of Development

The described methods are going to be tested in animal models.

Patent Status

Patent Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Mayer, Emeran A.

Other Information


Obesity, diabetes, hypertension, metabolic disease, therapeutic, weight loss, bariatric surgery, sleeve gastrectomy, gastric bypass

Categorized As